
    
      The purposes of this study are:

        1. to investigate the characteristics of treatment responders to galantamine by examining
           the clinical response of galantamine in patients with mild to moderate AD for 52 weeks.

        2. to examine the specific cognitive sub-domains that are more sensitive to galantamine
           administration.
    
  